#USA #Philadelphia #Biopharma #HealthVerity #Medeloop

HealthVerity eXOs: Revolutionizing Real-World Evidence in Biopharma

In the rapidly evolving landscape of medicine and pharmaceuticals, the need for accurate real-world data (RWD) has never been more pressing. Enter HealthVerity, a leader in RWD technologies, with their new platform: HealthVerity eXOs. Launched on September 30, 2025, this platform is powered by Medeloop's advanced AI technology and promises to transform how biopharma companies generate and utilize data for their operations.

The Driving Force Behind HealthVerity eXOs

HealthVerity eXOs is specifically designed to address the challenges biopharma companies face, particularly in launching products. The biopharmaceutical sector operates under substantial pressure; with fewer than 24% of launches meeting sales forecasts, the stakes are high. This new platform mitigates uncertainty in drug launches by providing timely insights based on real-world evidence. HealthVerity eXOs enables teams to swiftly design and execute a variety of studies, significantly reducing the time and cost compared to traditional methods.

Andrew Kress, CEO of HealthVerity, emphasized this point, stating, "For the first time, small and mid-sized biopharma can generate regulatory-grade evidence instantly—without sacrificing rigor or trust. HealthVerity eXOs empowers unlimited exploration, enabling teams to move from inquiry to insight without delay."

How It Works: Speed and Accessibility

The platform operates on a nationwide dataset of verified RWD and leverages a conversational AI interface, allowing users from various backgrounds, not just data scientists, to access complex analytics through simple, English-based prompts. Once a question is posed, HealthVerity eXOs delivers auditable insights in mere minutes. This level of speed and transparency ensures that stakeholders can trust the methods used and results produced.

Mark Booth, Head of Portfolio Strategy for Rare Disease at Chiesi USA, noted, "With HealthVerity eXOs, our team of non-coders can ask simple questions and get almost immediate insights. That allows us to refine tactics more confidently."

Proven Success and Early Adoption

Early adopters of the HealthVerity eXOs platform have already begun to validate its capabilities. Chris Pashos, Ph.D., Head of Real-World Evidence at Argenx, remarked, "HealthVerity eXOs has provided transparent cohort and coding logic and audit-ready outputs almost instantly, enabling us to accelerate our efforts without compromising rigor."

This platform not only enhances the accuracy of medical affairs and commercial strategies but also supports regulatory requirements. Stakeholders across the biopharma industry are already seeing transformative impacts on their decision-making processes.

The Partnership that Made It Possible

The introduction of HealthVerity eXOs is the result of a strategic partnership with Medeloop, a company specializing in AI-native analytics. Rene Caissie, CEO of Medeloop, declared, "By layering Medeloop's agentic AI on top of HealthVerity's unmatched real-world data, we are empowering biopharma to harness data insights effectively, improving patient lives through quicker access to necessary treatments."

A New Era of Data-Driven Decisions

HealthVerity eXOs is now available for biopharma and academic institutions involved in discovery, development, launch, and post-market activities. As the industry continues to adapt to the rapid changes brought about by technology, solutions like HealthVerity eXOs are set to reshape how real-world evidence is utilized in decision-making processes.

For those interested in experiencing the platform firsthand, HealthVerity is offering a demo session and an upcoming webinar on October 15.

In conclusion, the launch of HealthVerity eXOs represents a significant leap forward in the pharmaceutical industry's approach to real-world evidence. By making the process more accessible and efficient, HealthVerity not only helps biopharma companies to operate more effectively but also plays a crucial role in enhancing patient outcomes through timely treatment options.